Our Mission
At Tolka AI Therapeutics, we are pioneering phage therapy to combat Mycobacterium abscessus—a formidable pathogen known for its intrinsic and acquired antibiotic resistance. This bacterium, though responsible for only 0.03% of bacterial infections in the U.S., accounts for an astonishing 15% of global antibiotic use due to its resilient biofilms, impermeable cell envelope, and enzyme-mediated drug neutralization. Found ubiquitously in soil, water, and medical environments, M. abscessus poses a severe threat to patients with cystic fibrosis, immunodeficiencies, or preexisting lung conditions. Current treatments are lengthy, toxic, and increasingly ineffective, underscoring the urgent need for innovative alternatives.
Our mission is to harness the precision and adaptability of bacteriophages to develop safe, effective therapies that target M. abscessus at its core, reducing antibiotic reliance and advancing global health. With cutting-edge research and a patient-centered approach, we are redefining the fight against antimicrobial resistance.